Search Results - "Badros, Ashrof Z."
-
1
Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival
Published in Bone marrow transplantation (Basingstoke) (01-02-2019)“…The most common preparative regimen for autologous transplantation (ASCT) in myeloma (MM) consists of melphalan 200 mg/m 2 (MEL 200). Higher doses of melphalan…”
Get full text
Journal Article -
2
Final outcomes of escalated melphalan 280 mg/m 2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival
Published in Bone marrow transplantation (Basingstoke) (01-02-2019)“…The most common preparative regimen for autologous transplantation (ASCT) in myeloma (MM) consists of melphalan 200 mg/m (MEL 200). Higher doses of melphalan…”
Get full text
Journal Article -
3
Effect of the Proteasome Inhibitor Bortezomib in Combination with “DT-PACE” on Stem Cell Collection and Engraftment in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts)
Published in Blood (16-11-2004)“…In vitro data suggest that the addition of bortezomib to chemotherapy can enhance the anti-myeloma activity achieved with either therapy alone. We hypothesized…”
Get full text
Journal Article -
4
Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts)
Published in Blood (16-11-2004)“…Bcl-2 acts as an important regulator of the mitochondrial pathway of apoptosis and promotes resistance of MM cells to chemotherapy. The Bcl-2 antisense…”
Get full text
Journal Article